[Fludarabine as primary therapeutic drug in chronic lymphatic leukemia].
Hallek
M
M
Klinikum, Universität München Grosshadern, Marchioninistrasse 15, 81377 München. mhallek@med3.med.uni-muenchen.de
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D002699:Chlorambucil / Q000009:adverse effects / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D015996:Survival Rate; D016896:Treatment Outcome; D014740:Vidarabine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*
D002699:Chlorambucil; D014740:Vidarabine; C024352:fludarabine
Fludarabin als primäres Therapeutikum bei chronischer lymphatischer Leukämie.